Malaria vaccine development: Lessons from the field

European Journal of Immunology

Volumn 39, Issue 8, 2009, Pages 2007-2010

  Todryk, Stephen ^a   Bejon, Philip ^b  

^a NORTHUMBRIA UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Immune responses; Malaria; Vaccination

Indexed keywords

AMA 1 VACCINE; ERYTHROCYTE MEMBRANE PROTEIN 1; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MALARIA VACCINE; MSP 1 VACCINE; MSP 3 VACCINE; RTS S VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VACCINE; VIRUS VECTOR; PARASITE ANTIGEN;

ANTIBODY RESPONSE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG EFFICACY; GENETIC ASSOCIATION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INNATE IMMUNITY; MALARIA; MALARIA CONTROL; NONHUMAN; PARASITE TRANSMISSION; PARASITE VIRULENCE; PLASMODIUM; PREDICTION; PRIORITY JOURNAL; REVIEW; VACCINATION; ANIMAL; ARTICLE; BIOLOGICAL MODEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; GROWTH, DEVELOPMENT AND AGING; IMMUNITY; IMMUNOLOGY; LIFE CYCLE; MALARIA FALCIPARUM; PLASMODIUM FALCIPARUM;

ANIMALS; ANTIGENS, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNITY; LIFE CYCLE STAGES; MALARIA VACCINES; MALARIA, FALCIPARUM; MODELS, IMMUNOLOGICAL; PLASMODIUM FALCIPARUM;

EID: 70249129061     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200939529     Document Type: Review

References (40)

1. Snow, R. W. et al., Nature 2005. 434: 214-217.
2. Langhorne, J. et al., Nat. Immunol. 2008. 9: 725-732.
3. Pombo, D. J. et al., Lancet 2002. 360: 610-617.
4. Bull, P. C. and Marsh, K., Trends Microbiol. 2002. 10: 55-58.
5. Bull, P. C. et al., Nat. Med. 1998. 4: 358-360.
6. Mackintosh, C. L. et al., Int. J. Parasitol. 2008. 38: 1445-1454.
7. Bull, P. C. et al., PLoS Pathog. 2005. 1: e26.
8. Recker, M. et al., Nature 2004. 429: 555-558.
9. McCallum, F. J. et al., PLoS ONE 2008. 3: e3571.
10. Iriemenam, N. C. et al., Vaccine 2009. 27: 62-71.
11. Osier, F. H. et al., Infect. Immun. 2008. 76: 2240-2248.
12. Roussilhon, C. et al., PLoS Med. 2007. 4: e320.
13. Kinyanjui, S. M. et al., J. Infect. Dis. 2004. 190: 1527-1533.
14. Bejon, P. et al., Infect. Immun. 2009. 77: 1917-1923.
15. Gray, J. C. et al., Clin. Chem. 2007. 53: 1244-1253.
16. Miura, K. et al., J. Immunol. 2008. 181: 8776-8783.
17. Ogutu, B. R. et al., PLoS ONE 2009. 4: e4708.
18. Sirima, S. B. et al., Vaccine 2007. 25: 2723-2732.
19. Thera, M. A. et al., PLoS ONE 2008. 3: e1465.
20. Spring, M. D. et al., PLoS ONE 2009. 4: e5254.
21. Hoffman,S. L. et al., J. Infect. Dis. 2002. 185: 1155-1164.
22. Calle, J. M. et al., J. Immunol. 1992. 149: 2695-2701.
23. Calvo-Calle, J. M. et al., J. Immunol. 2005. 175: 7575-7585.
24. Marsh, K. et al., Trans. R. Soc. Trop. Med. Hyg. 1988. 82: 532-537.
25. Bojang,K. A. et al., Vaccine 2005. 23: 4148-4157.
26. Bejon, P. et al., N. Engl. J. Med. 2008. 359: 2521-2532.
27. Sun, P. et al., J. Immunol. 2003. 171: 6961-6967.
28. Hill, A. V., Annu. Rev. Genet. 2006. 40: 469-486.
29. Todryk, S. M. et al., PLoS ONE 2008. 3: e2027.
30. Migot-Nabias, F. et al., Trans. R. Soc. Trop. Med. Hyg. 2000. 94: 557-562.
31. Perlaza, B. L. et al., Eur. J. Immunol. 2008. 38: 2610-2615.
32. Webster, D. P. et al., Proc. Natl. Acad. Sci. USA 2005. 102: 4836-4841.
33. Bejon, P. et al., PLoS Clin. Trials 2006. 1: e29.
34. Walther, M. et al., Infect. Immun. 2006. 74: 2706-2716.
35. Thompson, F. M. et al., PLoS ONE 2008. 3: e1493.
36. Ghani, A. C. et al., PLoS ONE 2009. 4: e4383.
37. O'Meara, et al., Lancet 2008. 372: 1555-1562.
38. Lindblade, K. A. et al., JAMA 2004. 291: 2571-2580.
39. Gosling, R. D. et al., Malar. J. 2008. 7: 132.
40. Okell, L. C. et al., PLoS Med. 2008. 5: e226.